ACRO Biomedical Co

ACRO Biomedical Co ROCE

The Return on Capital Employed (ROCE) of ACRO Biomedical Co (6748.TWO) as of Nov 17, 2026 is -8.41 %. In the previous year, Return on Capital Employed (ROCE) was -10.62 % — a change of -20.80% (higher).

ROCE

-8.41 %

YoY

-20.80%

Last updated:

In 2025, ACRO Biomedical Co's return on capital employed (ROCE) was -8.41 %, a -20.80% increase from the -10.62 % ROCE in the previous year.

The ACRO Biomedical Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-26.34 TWD
Jan 1, 2020
-31.37 TWD
Jan 1, 2021
-41.19 TWD
Jan 1, 2022
-16.58 TWD
Jan 1, 2023
-7.09 TWD
Jan 1, 2024
-10.62 TWD
Jan 1, 2025
-8.41 TWD
The ACRO Biomedical Co ROCE history
YEARROCEYoY
-8.41 %-20.80%
-10.62 %+49.69%
-7.09 %-57.22%
-16.58 %-59.75%
-41.19 %+31.31%
-31.37 %+19.11%
-26.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co., Ltd. generates revenue through the development and production of biomaterial medical devices, primarily focusing on collagen scaffolds for tissue engineering and regenerative medicine. The company offers products such as ABCcolla Collagen Bone Graft, ABCcolla Collagen Matrix, ABCcolla Collagen Matrix Powder, ABCcolla Scar Spray, and ABCcolla External Aesthetic Restoration Prosthesis, all derived from pig skin and pig bone. These products are sold to healthcare providers and medical institutions involved in tissue engineering and regenerative medicine procedures. The firm also engages in international trade and technical services related to its products, expanding its market reach beyond local healthcare sectors. The company's revenue streams are driven by the sale of its specialized collagen-based medical devices, which are designed for applications in tissue repair and aesthetic restoration. ABCcolla Collagen Bone Graft targets bone regeneration, while ABCcolla Collagen Matrix and its variants support soft tissue engineering. ABCcolla Scar Spray addresses scar management, and the External Aesthetic Restoration Prosthesis serves cosmetic and reconstructive needs. These products cater to medical professionals seeking advanced solutions in regenerative medicine. ACRO Biomedical's business model relies on direct sales to healthcare institutions and international trade channels. The firm's focus on pig-derived collagen products positions it as a supplier for tissue engineering applications, with a strong emphasis on regenerative medicine. Technical services complement product sales, enhancing customer retention and recurring revenue opportunities. The company's product portfolio is tailored to meet the specific demands of medical professionals in tissue repair and aesthetic restoration markets. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling ACRO Biomedical Co's Return on Capital Employed (ROCE)

ACRO Biomedical Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing ACRO Biomedical Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

ACRO Biomedical Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in ACRO Biomedical Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about ACRO Biomedical Co stock

Return on Capital Employed (ROCE) of ACRO Biomedical Co is -8.41 % in 2025.

Return on Capital Employed (ROCE) of ACRO Biomedical Co changed from -10.62 % to -8.41 %, representing a -20.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) ACRO Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s ACRO Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co